Previous 10 | Next 10 |
The KWEB ETF has been battered significantly as investors left Chinese Internet stocks in a hurry since 2021. However, we could be in the late stage of the current malaise. Our price action analysis suggests that the worst in Chinese Internet stocks seems to have been priced in. KWEB'...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, yesterday announced the opening of a new regional office in Basel, Switzerland. BeiGene has built a European organization, inc...
Data from four pivotal trials continue to build evidence base for BRUKINSA ® (zanubrutinib) in B-cell malignancies Pipeline showing promise with early data for BGB-11417 , a BCL-2 inhibitor, as monotherapy and in combination with zanubrutinib BeiGene (NA...
China’s leading biotechnology and other health care companies have continued to grow revenues rapidly over the past two years and are expected to see strong growth in the years to come. Recently, concerns over domestic regulation, increased domestic competition, US Food and Dru...
A group of pharma companies focused on ant-TIGIT class of drugs are trading sharply lower in the pre-market Wednesday after French pharma giant Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced that a similar treatment failed in a late-stage trial for non-small cell lung cancer (NSCLC). The global ...
OrbiMed Asia V plans to raise $1.1 billion, OrbiMed Flagship IX seeks $1.9 billion and OrbiMed Royalty & Credit Opportunities $1.75 billion. Shanghai Jemincare Pharmaceuticals out-licensed global rights (ex-China) for a novel pain medication to Orion Corporation, a Finnish pharmac...
BeiGene press release (NASDAQ:BGNE): Q1 GAAP EPADS of -$4.24 beats by $1.08. Revenue of $306.63M (-49.4% Y/Y) beats by $6.22M. For further details see: BeiGene GAAP EPADS of -$4.24 beats by $1.08, revenue of $306.63M beats by $6.22M
Recorded product revenue of $261.6 million for the first quarter, representing a 146% increase from $106.1 million in the prior year period BRUKINSA product revenue increased 372% globally versus the first quarter of 2021, led by growth in U.S. and China New global c...
China's National Medical Products Administration (NMPA) granted conditional approval to BeiGene (NASDAQ:BGNE) and Amgen's (NASDAQ:AMGN) Blincyto injection to treat children with relapsed or refractory (R/R) CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL)....
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administra...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...